Share This

Public company info - Kingworld Medicines Group Ltd. , 01110.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Kingworld Medicines Group Ltd., 01110.HK - Company Profile
Chairman Zhao Li Sheng
Share Issued (share) 623,000,000
Par Currency Hong Kong Dollar
Par Value 0.1
Industry Medicine
Corporate Profile Business Summary: The Group is principally engaged in (i) distribution of imported branded pharmaceutical and healthcare products in the PRC; and (ii) manufacturing and sales of electrotherapeutic, physiotherapeutic devices and general medical examination devices. Performance for the year: Revenue of the Group for the Year Under Review was approximately RMB977,928,000, representing a decrease of approximately RMB100,915,000 or 9.4% from approximately RMB1,078,843,000 for the year ended 31 December 2018. For the Year Under Review, profit from operations for the Group amounted to approximately RMB76,744,000, representing an increase of approximately RMB7,898,000 or 11.5% from approximately RMB68,846,000 for the year ended 31 December 2018. For the Year Under Review, profit before taxation for the Group amounted to approximately RMB69,809,000, representing a decrease of approximately RMB571,000 or 0.8% from approximately RMB70,380,000 for the year ended 31 December 2018. For the Year Under Review, profit for the year attributable to owners of the Company amounted to approximately RMB43,427,000, representing an increase of approximately RMB2,422,000 or 5.9% from approximately RMB41,005,000 for the year ended 31 December 2018. Business Review The Group has been committed to developing a wellestablished upstream and downstream supply chain system for the greater health products and services industry for the past 25 years. Currently, it has a business footprint covers more than 34 provinces and cities in China. From 2009 to 2014, the Group was among the Top 100 Import Enterprises of Pharmaceutical and Healthcare Products for six consecutive years and was named as one of the Top 5 Sales Enterprises of Chinese Patent Medicines in terms of sales in 2013. The Group was rewarded as the Guangdong Province Enterprise of Observing Contract and Valuing Credit for five consecutive years, and was also ranked among Shenzhen Top 500 Enterprises in 2018 and 2019 and continued to be recognised as a “Shenzhen Timehonoured Brand” in 2019. The Group is a globally leading and well-known omnichannel enterprise with a complete supply chain in the greater health products and services industry in China. It also provides high-end logistics management services, business-to-customer (B2C) trading services and data services to major leading pharmaceutical and healthcare product suppliers, manufacturers and distributors, and is a pharmaceutical and healthcare product supply chain management services enterprise integrated with logistics, product and information. The three major business segments of the Group in the greater health services industry are: Pharmaceutical products segment: acting as an agent and distributor of high-quality and well-known pharmaceutical products from overseas, including the Nin Jiom (京都念慈菴) product series and the Taiko Seirogan (喇叭牌正露丸); Healthcare products segment: distributing high-quality and well-known healthcare products from overseas, including the Culturelle (康萃樂) probiotics product series, the Lifeline Care maternal and infant fish oil nutrient product series, “Global Slimming” product series and product series of medicated oils for external use; and Medical devices segment: undertaking research and development (R&D), manufacturing and production of medical devices. For the Year Under Review, revenue from the pharmaceutical products segment amounted to approximately RMB633,700,000, representing a slight increase of 2.0% as compared to the same period last year and accounting for 64.8% of the Group’s total revenue. Revenue from the healthcare products segment was approximately RMB151,114,000, representing a decrease of 40.2% as compared to the same period last year and accounting for 15.5% of the Group’s total revenue. Revenue from the medical devices segment amounted to approximately RMB193,114,000, representing a decrease of 5.8% as compared to the same period last year and accounting for 19.7% of the Group’s total revenue. Prospects: The Group will be celebrating the 10th anniversary of its listing in 2020. In 2020, the Group will continue to introduce new products, optimise its product structure, expedite the implementation of projects under negotiations and enrich its product portfolio. On the other hand, for the purpose of strengthening the development of the Group’s upstream and downstream supply chain systems in the greater health industry, the capital operating team of the Group will continue to facilitate the Group’s business in the greater health services sector by actively identifying production enterprises and upstream manufacturers with the greater health concept and potential product market, especially those domestic pharmaceutical enterprises with the Good Manufacturing Practices (“GMP”) certification. In addition, the Group will utilise scientific big data analysis in its “SMART System” to promote different businesses and formulate comprehensive marketing plan and arrangement of its product portfolio to meet consumers’ needs and respond to the changes in the competitive landscape. In the future, based on the actual situation, the Group will concentrate its resources on developing its product portfolio that generate higher profit and long-term stable income. The Group will boost sales and enhance product core competitiveness by ascertaining target consumers’ needs, opening up market gaps, exploring new development opportunities and utilising new marketing strategies and plans. In 2020, the Group will continue to advance the expansion and deployment on upstream business, research and development, as well as expedite the launching of Chinese medicines with probiotics. Meanwhile, the introduction of new products will be accelerated by speeding up the collaborative projects in relation to probiotics with the HKUST, which aims to utilise HKUST’s research and development capabilities and the Group’s analysis and assessment of future market trends to develop Chinese medicines with probiotics and anti-inflammatory properties. This cooperation will enable the Group to deepen product lines and accommodate the various demands of a broader spectrum of consumers. In addition, the Group is negotiating with a French national brand regarding their cooperation in the Hong Kong and Macao markets. The launching of “Jianfu Capsules (鳳寶牌健婦膠囊)” in both the Hong Kong and Macao markets as well as Mainland China will be accelerated to give new impetus to the Group’s development. In the year ahead, the Group will conduct an independent internal audit for the OTC channels, e-commerce channels and the Hong Kong and Macao markets respectively in accordance with the characteristics of different channels, so as to enhance market penetration rate and strengthen profitability of these channels. Different channels will be managed and evaluated by respective experienced professional managers to develop a respective operating frameworks for business divisions, so as to construct a pipeline of steady coordinated development between three business segments. Furthermore, the Group will take advantage of Macao’s development policies by actively deploying business in Macao. The Group will position Hong Kong and Macao as the places to test and promote new products of the Group. In the future, the Group will continue to actively promote the implementation of the Shenzhen-Hong Kong Chinese Pharmaceutical Demonstration Platform, aiming to strengthen the development of the Chinese pharmaceutical industry in the Greater Bay Area. Construction of the Hong Kong Chinese Pharmaceutical Demonstration Platform is an important tool for implementing the instruction of Xi Jinping, President of the PRC, on reviving the Chinese pharmaceutical industry. This direction is also an important vehicle in facilitating the integrated development of the Chinese pharmaceutical industry in Shenzhen, Hong Kong and Macao and hastening the integration of the Chinese pharmaceutical industry in Hong Kong and Macao with that in the Mainland, as set out in the Plan. It will also be a measure that can boost the modernisation and internationalisation of Chinese medicines and develop Shenzhen to become a bridgehead for pharmaceutical industry-related cooperation along the “Belt and Road”. In conclusion, the domestic and global economic environment are complex and challenging. Meanwhile, the COVID-19 outbreak will have short-term effect on the macroeconomic environment in the first half of 2020, but the Group are of the view that such risks are within the Group's control. The Group is optimistic about its long-term development. In 2020, the Group will be facing both opportunities and risks. Nevertheless, despite the potential turbulence in the macroeconomic environment, the Group considers the current situation as a good opportunity to further its business development. In 2020, the Group will further build a sound foundation by focusing on an orderly and effective reinforcement of the competitiveness of its core products, and conducting cost control in order to maintain profitability, enhancing financial risk management to maintain sufficient cash flow, so as to protect the return on investment of the Shareholders and other stakeholders. At the same time, the Group will expand its development in the greater health industry in order to develop the Company to become a domestic leading and world-renowned enterprise with a well-established upstream and downstream supply chain for the greater health products and services industry.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.